Key clinical point: Pediatric-onset MS has a unique phenotype, and the choice of treatment may influence the frequency of fatigue and mood disorders among these patients.
Major finding: Anxiety and fatigue were associated with disease-modifying therapy efficacy in pediatric-onset MS.
Study details: An analysis of data from MS Partners Advancing Technology and Health Solutions (MS-PATHS).
Disclosures: Biogen sponsors MS-PATHS. Dr. Rensel has received funding from several companies, including Biogen, Novartis, Serono, and Teva.
Rensel M et al. ACTRIMS 2020, Abstract P042.